434 related articles for article (PubMed ID: 26057757)
41. LASER RESENSITIZATION OF MEDICALLY UNRESPONSIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Efficacy and Implications.
Luttrull JK; Chang DB; Margolis BW; Dorin G; Luttrull DK
Retina; 2015 Jun; 35(6):1184-94. PubMed ID: 25650711
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
43. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
44. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
45. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
46. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
[TBL] [Abstract][Full Text] [Related]
47. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
[TBL] [Abstract][Full Text] [Related]
49. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.
Yuzawa M; Fujita K; Wittrup-Jensen KU; Norenberg C; Zeitz O; Adachi K; Wang EC; Heier J; Kaiser P; Chong V; Korobelnik JF
Ophthalmology; 2015 Mar; 122(3):571-8. PubMed ID: 25439429
[TBL] [Abstract][Full Text] [Related]
50. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.
Aghdam KA; Pielen A; Framme C; Junker B
Eur J Ophthalmol; 2016 Aug; 26(5):473-8. PubMed ID: 26868007
[TBL] [Abstract][Full Text] [Related]
51. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
52. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
[TBL] [Abstract][Full Text] [Related]
53. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
54. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
[TBL] [Abstract][Full Text] [Related]
55. Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.
de Oliveira Dias JR; Xavier CO; Maia A; de Moraes NS; Meyer C; Farah ME; Rodrigues EB
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):91-4. PubMed ID: 25559518
[TBL] [Abstract][Full Text] [Related]
56. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Kawasaki R; Sekiryu T; Okada AA; Iida T
Am J Ophthalmol; 2015 Apr; 159(4):627-33. PubMed ID: 25555799
[TBL] [Abstract][Full Text] [Related]
57. Aflibercept anti-vascular endothelial growth factor therapy in vitrectomized eyes with neovascular age-related macular degeneration.
Jung JJ; Hoang QV; Arain MZ; Chang S
Acta Ophthalmol; 2016 May; 94(3):e249-50. PubMed ID: 26401896
[No Abstract] [Full Text] [Related]
58. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
Chan CK; Jain A; Sadda S; Varshney N
Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
[TBL] [Abstract][Full Text] [Related]
59. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal Aflibercept for Neovascular AMD: Short-Term Clinical Effects of Intravitreal Aflibercept Injection as a Predictor of Long-Term Results.
Liu EM; Shah G; Blinder KJ; Smith BT; Thomas MA
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1021-7. PubMed ID: 26599244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
